Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Research output: Research - peer-reviewJournal article – Annual report year: 2018

  • Author: Sølund, Christina

    University of Copenhagen

  • Author: Hallager, Sofie

    University of Copenhagen

  • Author: Pedersen, Martin S.

    University of Copenhagen, Denmark

  • Author: Fahnøe, Ulrik

    University of Copenhagen, Denmark

  • Author: Ernst, Anja

    Aalborg University

  • Author: Krarup, Henrik B.

    Aalborg University

  • Author: Røge, Birgit T.

    Hospital Lillebaelt

  • Author: Christensen, Peer B.

    University of Southern Denmark

  • Author: Laursen, Alex L.

    Aarhus University

  • Author: Gerstoft, Jan

    University of Copenhagen

  • Author: Bélard, Erika

    University of Copenhagen

  • Author: Madsen, Lone G.

    University of Copenhagen

  • Author: Schønning, Kristian

    University of Copenhagen

  • Author: Pedersen, Anders G.

    Disease Intelligence and Molecular Evolution, Department of Bio and Health Informatics, Technical University of Denmark, Kemitorvet, 2800, Kgs. Lyngby, Denmark

  • Author: Bukh, Jens D.

    University of Copenhagen

  • Author: Weis, Nina

    University of Copenhagen

View graph of relations

Objectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark. Materials and Methods: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause. Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). The most frequent reasons for not starting treatment among 356 (51%) patients were non-adherence to medical appointments (n = 107/30%) and ongoing substance use (n = 61/17%). Treatment failure with viral relapse occurred in 19 (5.5%) patients, who were more likely to have failed previous treatment OR 4.53 (CI: 1.59–12.91). Conclusions: In this nationwide cohort study, we found non-adherence to medical appointments and active substance use to be major obstacles for DAA treatment initiation. Our findings highlight the need for interventions that can overcome these barriers and increase the number of patients who can initiate and benefit from curative DAA treatment.

Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume53
Issue number7
Pages (from-to)849-856
Number of pages8
ISSN0036-5521
DOIs
StatePublished - 2018
CitationsWeb of Science® Times Cited: 0

    Research areas

  • Barriers to treatment, DAA, Direct Acting Antivirals, Factors associated with treatment, HCV, Hepatitis C virus, Liver cancer, Liver disease, Treatment initiation
Download as:
Download as PDF
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
PDF
Download as HTML
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
HTML
Download as Word
Select render style:
APAAuthorCBE/CSEHarvardMLAStandardVancouverShortLong
Word

ID: 148517357